Literature DB >> 18644718

Synthesis and biological evaluation of novel 1-O- and 14-O-derivatives of oridonin as potential anticancer drug candidates.

Jinyi Xu1, Jingyi Yang, Qian Ran, Lei Wang, Jie Liu, Zhixuan Wang, Xiaoming Wu, Weiyi Hua, Shengtao Yuan, Luyong Zhang, Mingqin Shen, Yongfang Ding.   

Abstract

Novel 1-O- and 14-O-derivatives of oridonin were synthesized and biologically evaluated. All of the derivatives exhibited stronger cytotoxicity against six cancer cell lines (BGC-7901, SW-480, HL-60, BEL-7402, A549, and B16) than oridonin in vitro, and some of them were more potent than oridonin and cyclophosphamide in vivo. Compounds Ib and IIg were the most potent with the IC(50) values of 0.84 microM for Ib in HL-60 cell and 1.00 microM for IIg in BEL-7402 cell.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18644718     DOI： 10.1016/j.bmcl.2008.06.097

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  14 in total

1.  Novel hybrids of natural oridonin-bearing nitrogen mustards as potential anticancer drug candidates.

Authors:  Shengtao Xu; Lingling Pei; Chengqian Wang; Yun-Kai Zhang; Dahong Li; Hequan Yao; Xiaoming Wu; Zhe-Sheng Chen; Yijun Sun; Jinyi Xu
Journal:  ACS Med Chem Lett       Date:  2014-05-28       Impact factor: 4.345

2.  Overcoming synthetic challenges of oridonin A-ring structural diversification: regio- and stereoselective installation of azides and 1,2,3-triazoles at the C-1, C-2, or C-3 position.

Authors:  Chunyong Ding; Yusong Zhang; Haijun Chen; Christopher Wild; Tianzhi Wang; Mark A White; Qiang Shen; Jia Zhou
Journal:  Org Lett       Date:  2013-07-08       Impact factor: 6.005

3.  Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility.

Authors:  Chunyong Ding; Yusong Zhang; Haijun Chen; Zhengduo Yang; Christopher Wild; Lili Chu; Huiling Liu; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2013-06-19       Impact factor: 7.446

Review 4.  Discovery and development of natural product oridonin-inspired anticancer agents.

Authors:  Ye Ding; Chunyong Ding; Na Ye; Zhiqing Liu; Eric A Wold; Haiying Chen; Christopher Wild; Qiang Shen; Jia Zhou
Journal:  Eur J Med Chem       Date:  2016-06-13       Impact factor: 6.514

5.  ent-Kaurane-based regio- and stereoselective inverse electron demand hetero-Diels-Alder reactions: synthesis of dihydropyran-fused diterpenoids.

Authors:  Chunyong Ding; Lili Wang; Haijun Chen; Christopher Wild; Na Ye; Ye Ding; Tianzhi Wang; Mark A White; Qiang Shen; Jia Zhou
Journal:  Org Biomol Chem       Date:  2014-11-14       Impact factor: 3.876

6.  Synthesis and biological evaluation of novel furozan-based nitric oxide-releasing derivatives of oridonin as potential anti-tumor agents.

Authors:  Dahong Li; Lei Wang; Hao Cai; Yihua Zhang; Jinyi Xu
Journal:  Molecules       Date:  2012-06-18       Impact factor: 4.411

Review 7.  Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance.

Authors:  Xi Liu; Jimin Xu; Jia Zhou; Qiang Shen
Journal:  Genes Dis       Date:  2020-07-05

Review 8.  Oridonin, a Promising ent-Kaurane Diterpenoid Lead Compound.

Authors:  Dahong Li; Tong Han; Jie Liao; Xu Hu; Shengtao Xu; Kangtao Tian; Xiaoke Gu; Keguang Cheng; Zhanlin Li; Huiming Hua; Jinyi Xu
Journal:  Int J Mol Sci       Date:  2016-08-24       Impact factor: 5.923

9.  Geridonin and paclitaxel act synergistically to inhibit the proliferation of gastric cancer cells through ROS-mediated regulation of the PTEN/PI3K/Akt pathway.

Authors:  Sai-Qi Wang; Cong Wang; Li-Ming Chang; Kai-Rui Zhou; Jun-Wei Wang; Yu Ke; Dong-Xiao Yang; Hong-Ge Shi; Ran Wang; Xiao-Li Shi; Li-Ying Ma; Hong-Min Liu
Journal:  Oncotarget       Date:  2016-11-08

Review 10.  Solubility and Bioavailability Enhancement of Oridonin: A Review.

Authors:  Yuanyuan Zhang; Shaohua Wang; Mengmeng Dai; Jijuan Nai; Liqiao Zhu; Huagang Sheng
Journal:  Molecules       Date:  2020-01-14       Impact factor: 4.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.